实用药物与临床
實用藥物與臨床
실용약물여림상
Practical Pharmacy and Clinical Remedies
2015年
10期
1171-1173
,共3页
何颖%刘妍%万成福%宋涛
何穎%劉妍%萬成福%宋濤
하영%류연%만성복%송도
带状疱疹后神经痛%丁丙诺菲透皮贴剂%加巴喷丁
帶狀皰疹後神經痛%丁丙諾菲透皮貼劑%加巴噴丁
대상포진후신경통%정병낙비투피첩제%가파분정
Postherpetic neuralgia%Buprenorphine transdermal patches%Gabapentin
目的 观察加巴喷丁联合小剂量丁丙诺菲透皮贴治疗老年带状疱疹后神经痛( PHN)的临床效果. 方法 60例PHN患者随机分为对照组和试验组. 对照组:单独应用加巴喷丁;试验组:加巴喷丁联合应用丁丙诺菲透皮贴5 mg,每7天贴敷1次. 根据患者疼痛情况逐渐调整加巴喷丁剂量,直至患者疼痛评分<4 分,两组患者加巴喷丁最大剂量为1 800 mg/d. 治疗8 周后,记录两组患者用药前及用药后2、4、8 周的疼痛评分( VAS)、睡眠评分、加巴喷丁日剂量及不良反应发生率. 结果 治疗后,两组患者 VAS 评分明显降低( P <0. 01);治疗后4、8周,试验组VAS评分明显低于对照组(P<0. 05). 治疗后,两组患者睡眠质量明显改善(P<0. 01);试验组加巴喷丁的用量较小(P<0. 05);联合应用丁丙诺菲透皮贴可以显著降低加巴喷丁相关不良反应头晕、嗜睡的发生率(P<0. 05). 结论 加巴喷丁联合小剂量丁丙诺菲透皮贴对PHN患者的临床效果优于单独应用加巴喷丁,不良反应较小,可安全用于临床.
目的 觀察加巴噴丁聯閤小劑量丁丙諾菲透皮貼治療老年帶狀皰疹後神經痛( PHN)的臨床效果. 方法 60例PHN患者隨機分為對照組和試驗組. 對照組:單獨應用加巴噴丁;試驗組:加巴噴丁聯閤應用丁丙諾菲透皮貼5 mg,每7天貼敷1次. 根據患者疼痛情況逐漸調整加巴噴丁劑量,直至患者疼痛評分<4 分,兩組患者加巴噴丁最大劑量為1 800 mg/d. 治療8 週後,記錄兩組患者用藥前及用藥後2、4、8 週的疼痛評分( VAS)、睡眠評分、加巴噴丁日劑量及不良反應髮生率. 結果 治療後,兩組患者 VAS 評分明顯降低( P <0. 01);治療後4、8週,試驗組VAS評分明顯低于對照組(P<0. 05). 治療後,兩組患者睡眠質量明顯改善(P<0. 01);試驗組加巴噴丁的用量較小(P<0. 05);聯閤應用丁丙諾菲透皮貼可以顯著降低加巴噴丁相關不良反應頭暈、嗜睡的髮生率(P<0. 05). 結論 加巴噴丁聯閤小劑量丁丙諾菲透皮貼對PHN患者的臨床效果優于單獨應用加巴噴丁,不良反應較小,可安全用于臨床.
목적 관찰가파분정연합소제량정병낙비투피첩치료노년대상포진후신경통( PHN)적림상효과. 방법 60례PHN환자수궤분위대조조화시험조. 대조조:단독응용가파분정;시험조:가파분정연합응용정병낙비투피첩5 mg,매7천첩부1차. 근거환자동통정황축점조정가파분정제량,직지환자동통평분<4 분,량조환자가파분정최대제량위1 800 mg/d. 치료8 주후,기록량조환자용약전급용약후2、4、8 주적동통평분( VAS)、수면평분、가파분정일제량급불량반응발생솔. 결과 치료후,량조환자 VAS 평분명현강저( P <0. 01);치료후4、8주,시험조VAS평분명현저우대조조(P<0. 05). 치료후,량조환자수면질량명현개선(P<0. 01);시험조가파분정적용량교소(P<0. 05);연합응용정병낙비투피첩가이현저강저가파분정상관불량반응두훈、기수적발생솔(P<0. 05). 결론 가파분정연합소제량정병낙비투피첩대PHN환자적림상효과우우단독응용가파분정,불량반응교소,가안전용우림상.
Objective To observe the effect of buprenorphine transdermal patches combined with gabapentin on gerontic patients with PHN. Methods Sixty patients were divided into experimental group and control group ran-domly. Patients in control group were orally administered gabapentin only,and patients of experimental group were ad-ministered gabapentin combined with buprenorphine transdermal patches 5 mg every 7 d. The doctor increased the do-ses of gabapentin according to the scores of pain ( VAS>4 ) gradually. The maximum dose of gabapentin was 1 800 mg/d in both groups. The VAS scores,sleep scores,doses of gabapentin and adverse reactions at each time point were recorded. Results There was a significant decline in VAS scores and sleep scores after treatment in the two groups ( P<0. 01). Compared with control group,the VAS scores and the doses of gabapentin were significantly lower at 4,8 weeks after treatment (P<0. 05). The incidence of dizzy and drowsiness were higher in control group (P<0. 05),but there was no significant difference in the incidence of other side effects. Conclusion The combination of buprenor-phine transdermal patches with gabapentin is effective and safe for the gerontic patients with PHN.